Novartis Signs License Agreement with MorphoSys to Develop and Commercialise Preclinical Inhibitors for Cancer

By Ashish Tripathi

Pharma Deals Review: Vol 2022 Issue 12 (Table of Contents)

Published: 21 Dec-2022

DOI: 10.3833/pdr.v2022.i12.2755     ISSN: 1756-7874

Section: Licensing



In a bid to bolster its preclinical pipeline, Novartis has entered into a licensing agreement with MorphoSys for US$23 M...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details